How to Buy Gold Fut...
Health Care: Drugs
Johnson & Johnson (JNJ: NYSE)
$58.93 0.32 | 0.55%
09/03/10 - 04:00 PM ET
7.53M / 13.57M
Vol / Avg. Vol:58.85 / 58.61
Open / Prev. Close:58.50 - 59.00
Today's Range:56.86 - 66.20
52 Wk Range:-8.51%
Performance YTD:TheStreet Rating:
Portfolios with JNJ
- Portfolio NameUser Type
- ContributorStocks to Buy During a Crash
- Contributor5 Market Heavyweights' Rece...
- Contributor9 Blue-Chips to Dump Immedi...
- Contributor4 Companies That Could Come...
- Contributor10 Most Attractively Valued...
- Contributor5 Undervalued Consumer Good...
- ContributorTop 10 Dow Dividend Stocks
- Contributor7 Low-Risk, High-Dividend S...
- Contributor10 Dow Stocks to Buy Now
- ContributorFast Money's Defensive Stocks
Latest JNJ Headlines from TheStreet
- Genzyme Sale Inevitable, Buysiders Say 09.01.10 | 12:09 am
- J&J: More Recalls, More Market Share Loss? 08.31.10 | 01:08 pm
- Dow Drops 141 Points on Consumer Woes 08.30.10 | 04:08 pm
- Web of Lies? Brands Hire to Secure Reputation 08.30.10 | 09:08 am
- CMED Gets Wave of Health: China Watch
08.30.10 | 06:08 am - J&J Recalls 2 Hip Replacement Systems For Problems 08.27.10 | 04:08 pm
- CEO: J&J Let Down Public, Must Work To Build Trust 08.27.10 | 03:08 pm
- J&J Recalls 2 Hip Replacement Systems For Problems 08.26.10 | 09:08 am
- 5 Market Heavyweights' Recent Picks 08.25.10 | 09:08 am
- Stocks Hit by Flight to Safety 08.24.10 | 04:08 pm
Press Releases for JNJ
- Long Term Data Presented At ESC 2010 Shed Further Light On The Benefit Of The CYPHER® Sirolimus Drug-Eluting Stent Compared To The ENDEAVOR® Zotarolimus-Eluting Stent In Important High-Risk Subgroups - Business Wire 09.02.10 | 08:09 am
- DePuy Orthopaedics Voluntarily Recalls ASR⢠Hip System - PR Newswire 08.26.10 | 08:08 am
- American Optometric Association Awards 1-DAY ACUVUE® TRUEYE⢠With Seal Of Acceptance For UV Absorbing Contact Lenses - PR Newswire 08.05.10 | 07:08 am
- Former McKinsey & Company Chairman And Managing Director Ian Davis Appointed To Johnson & Johnson Board Of Directors - PR Newswire 07.19.10 | 05:07 pm
- Johnson & Johnson To Host Analyst Conference Call On Second-Quarter Results - PR Newswire 07.13.10 | 10:07 am
- Johnson & Johnson Announces Definitive Agreement To Acquire Micrus Endovascular - PR Newswire 07.12.10 | 08:07 am
- Kick Start Your Dreams With A Chance To Win $2500 From ACUVUE® Brand Contact Lenses - PR Newswire 07.08.10 | 07:07 am
- Richard B. Sellars, Former Chairman And CEO Of Johnson & Johnson, Dies At 94 - PR Newswire 06.25.10 | 02:06 pm
- Biosense Webster Receives FDA Clearances For The CARTOXPRESS™ Software Module And LASSO® NAV Catheter For Its CARTO® XP System - Business Wire 06.23.10 | 02:06 pm
- Johnson & Johnson Highlights Growth Strategies For Its World-Leading Medical Devices & Diagnostics Segment - PR Newswire 06.03.10 | 08:06 am
Partner Headlines for JNJ
- How Patience Plus a Great Franchise Can Make You Money - Seeking Alpha 09.01.10 | 08:09 am
- Zacks Earnings Trends Highlights: Johnson & Johnson, Chevron and DuPont - Press Releases - Zacks 08.31.10 | 09:08 am
- Seven Reasons Why There Is No Double Dip - Seeking Alpha 08.31.10 | 09:08 am
- An Era of Multiple Compression: A Scenario Analysis and How to Invest in Equities - Seeking Alpha 08.31.10 | 09:08 am
- Stock Market News for August 30, 2010 - Market News - Zacks 08.30.10 | 10:08 am
- J&J Plagued by Product Recalls - Analyst Blog - Zacks 08.30.10 | 10:08 am
- FDA Committee Rejects Expanded Use of Jazz Drug on Abuse Concerns: Biotech's Latest Failures - Seeking Alpha 08.30.10 | 08:08 am
- Top 10 Dividend Stocks to Evaluate - Seeking Alpha 08.29.10 | 06:08 am
- CORRECTION - - UPDATE 4-J&J ortho unit recalls hip replacement systems - Reuters 08.26.10 | 02:08 pm
- The Market Is in Despair, So Now What? - Seeking Alpha 08.26.10 | 08:08 am
